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Targeting of activated plasma membrane receptors
to endocytic pathways is important in determining
the outcome of growth factor signaling. However,
the molecular mechanisms are still poorly under-
stood. Here, we show that the synaptotagmin-
related membrane protein E-Syt2 is essential for
rapid endocytosis of the activated FGF receptor
and for functional signal transduction during Xeno-
pus development. E-Syt2 depletion prevents an early
phase of activated FGF receptor endocytosis that
we show is required for ERK activation and the induc-
tion of the mesoderm. E-Syt2 interacts selectively
with the activated FGF receptor and with Adaptin-2,
and is required upstream of Ras activation and of
receptor autophosphorylation for ERK activation
and the induction of the mesodermal marker Xbra.
The data identify E-Syt2 as an endocytic adaptor
for the clathrin-mediated pathway whose function
is conserved in human and suggest a broader role
for the E-Syt subfamily in growth factor signaling.
INTRODUCTION
The fibroblast growth factors (FGFs) are powerful mitogens
whose disregulation has been associated with multiple forms
of cancers (Eswarakumar et al., 2005), and with cell transforma-
tion (Dvorak et al., 2006), angiogenesis (Murakami and Simons,
2008) and metastasis (Chaffer et al., 2007). Their action is also
essential for correct germ layer induction and organogenesis
during early metazoan development (Bottcher and Niehrs,
2005; Kimelman, 2006; Thisse and Thisse, 2005). FGF signaling
occurs via one of four receptor tyrosine kinases (RTKs), the FGF
receptors 1 to 4 (FGFR1–4), which transduce the FGF signal to
the ERK MAP-kinase (Umbhauer et al., 1995), PI3K, and PLCg
pathways (Sivak et al., 2005).
Endocytosis was originally thought to be ameans to extinguish
receptor signaling, permitting appropriate responses to sequen-
tial signaling events. However, active signalingmay continuewell
after RTK internalization (Baass et al., 1995) and the choice of
endocytic pathway can often determine the response to growth426 Developmental Cell 19, 426–439, September 14, 2010 ª2010 Elsfactors (Miaczynska et al., 2004). The endocytic pathway has
been found to determine signal strength, longevity, and intracel-
lular location, at least in part by directing signaling to appropriate
effector pathways (Le Borgne et al., 2005; Le Roy and Wrana,
2005; Polo et al., 2004; Vieira et al., 1996). Thus, the exactmanner
in which RTKs are internalized will more than often determine
the outcome of growth factor signaling.
Despite the wide-ranging biological importance of FGF
signaling, the role of receptor endocytosis in determining its
physiological outcome is still very poorly understood (Wiedlocha
and Sorensen, 2004). It is known that both the catalytic activity
and intracellular domains of the FGFRs are necessary for
receptor endocytosis (Citores et al., 2001; Sorokin et al., 1994).
Recent work has suggested that targeting activated RTKs
to the clathrin-dependent endocytic pathway rather than to non-
clathrin pathways is necessary if signaling is to be sustained
(Sigismund et al., 2008). But, it is still far from clear how activated
RTKs in general, and the FGFRs in particular, are selectively
recognized and targeted to any endocytic pathway.
We report that the Extended Synaptotagmin-like protein
E-Syt2 (Groer et al., 2008; Min et al., 2007) constitutes an early
endocytic adaptor for the FGFRs. E-Syt2 is essential for meso-
derm induction, and for functional FGFR endocytosis and ERK
activation during Xenopus embryogenesis. E-Syt2 interacts
highly selectively with activated FGFR on the plasma membrane
and with the clathrin adaptor complex Adaptin-2 (AP-2), pro-
viding a link between receptor activation and endocytosis that
is conserved in human.RESULTS
The Extended Synaptotagmin-like protein E-Syt2 is a membrane
protein of unknown function (Groer et al., 2008; Min et al., 2007).
However, E-Syt2 orthologs exist in animals as evolutionarily
distant as human and worm, suggesting an essential common
function (Figure 1A; see Figure S1A available online) (Groer
et al., 2008). The Xenopus ortholog of human E-Syt2 is predicted
to have an N-terminal trans-membrane (TM) domain and a SMP
(Synaptotagmin-like, Mitochondrial and lipid binding protein)
in silico predicted domain (Lee and Hong, 2006), followed by
three C2 domains (Figure 1A). E-Syt2 is maternally expressed
and is present throughout early Xenopus development, at least
as far as stage 40 (Figure S1B). By late gastrula/early neurula
(stages 11.5–18) expression is mainly associated with headevier Inc.
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Figure 1. Xenopus E-Syt2 Is Required for Induction of the Early Mesoderm Gene Xbra and for FGF Signaling
(A) Predicted structural domains of E-Syt2 orthologs, ‘‘x’’ Xenopus, ‘‘h’’ human, ‘‘Dm’’ Drosophila melanogaster, ‘‘Ce’’ Caenorhabditis elegans.
(B) Zygotic E-Syt2 expression depends on FGF signaling. FGF signaling was inhibited by the expression of the dominant-negative FGF receptor ‘‘XFD’’ (100, 200,
and 400 pg) in ventral marginal zone (VMZ) explants.
(C) In vivo Xbra expression is suppressed by E-Syt2 depletion. Dorsal blastomeres of four cell embryos were each injected equatorially with 0.75 pmol of Mo-C
and increasing amounts of HA-E-Syt2 mRNA and Xbra expression at stage 10.5 revealed by whole-mount in situ hybridization.
(D) E-Syt2 depletion suppresses ectopic induction of Xbra by activated FGFR1. Embryos were injected with 0.9 or 1.8 pmol Mo-B or Ctrl Mo and with 2.5 pg
constitutively active FGFR1 (CA-FGFR1) or 5 pg VRas.
(E) Activated FGFR1 (1.5 pg/cell, four cell embryos) induction of ectopic ERK activation in ACs was also suppressed by depletion of E-Syt2 (3 pmol MoC/cell).
(F) Depletion of E-Syt2 also suppresses FGF8-dependent differentiation. Embryos were unilaterally coinjected with FGF8 (2.5 pg), b-galactosidase (325 pg)
mRNAs, and E-Syt2 Mo-B or Ctrl Mo (2 pmol) and subjected to whole-mount in situ to reveal N-tubulin expression (blue). Purple staining (b-galactosidase activity
assay) indicates injected side of embryo.
See also Figure S1.
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E-Syt2, an Endocytic Adaptor for FGFRand dorsolateral mesoderm and at later stages (29–33) with eye,
cranial neural crest, and somites (Figure S1B).
E-Syt2 Is Required for Mesoderm Formation In Vivo
The expression pattern of E-Syt2 resembled that of FGFR1 (Lea
et al., 2009), suggesting that it might form part of the FGF synex-
pression group (Furthauer et al., 2002; Tsang et al., 2002).
Consistent with this, inhibition of FGF signaling in the marginal
zone of Xenopus embryos by expression of the dominant-nega-
tive receptor XFD (Amaya et al., 1991) inhibited the zygoticDevelopmenexpression of both E-Syt2 mRNA and the early mesodermal
marker Xbra, indicating that e-syt2 is an FGF-responsive gene
(Figure 1B). Specific depletion of E-Syt2 using antisense
Morpholinos (Figures S1C and S1D), in turn caused severe trunk
shortening, reminiscent of FGF inhibition (Chung et al., 2004;
Fletcher and Harland, 2008) andwas rescued by the introduction
of wild (wt) E-Syt2 but not of a mutant lacking the trans-
membrane domain (Figure 6A; Figures S1E and S1F). Trunk
shortening was also associated with a disruption of somatic
muscle formation (Figure S1G). Further, depletion of E-Syt2tal Cell 19, 426–439, September 14, 2010 ª2010 Elsevier Inc. 427
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E-Syt2, an Endocytic Adaptor for FGFRfrom the dorsal medial zone inhibited expression of the early
mesodermal marker Xbra, and this expression could be rescued
by low-level expression of E-Syt2 (Figure 1C). Together these
data suggested that E-Syt2 was required for early mesoderm
induction.
E-Syt2 Is Required for FGF Signaling
FGF signaling via the ERK MAP-kinase pathway is essential for
the induction and maintenance of mesoderm during Xenopus
embryogenesis (Amaya et al., 1993; Fletcher and Harland,
2008; Umbhauer et al., 1995). Xenopus animal cap (AC) explants
do not normally express mesoderm-specific genes. However,
activation of the FGF pathway, for example, by ectopic expres-
sion of constitutively active FGFR1 (CA-FGFR1), is sufficient
to induce mesodermal differentiation and the expression of
genes such as Xbra (Figure 1D). Depletion of E-Syt2 strongly
inhibited Xbra expression, while expression was fully rescued
by the constitutively active VRas (Figure 1D). Further, E-Syt2
depletion also inhibited ERK activation by CA-FGFR1, and this
activation was rescued by the reintroduction of E-Syt2 (Fig-
ure 1E). Thus, E-Syt2 was required for the induction of Xbra
expression and for ERK activation by the FGF pathway, and
acted upstream of Ras.
Ectopic FGF8 in Xenopus embryos induces the aberrant differ-
entiation of neurons within the embryonic ectoderm and hence
provides a further in vivo test for functional FGF signaling (Hard-
castle et al., 2000; Figure 1F). Depletion of E-Syt2 from embryos
severely attenuated the differentiation of ectopic neurons in
embryos unilaterally microinjected with FGF8 mRNA (Figure 1F).
This provided further confirmation that E-Syt2 was indeed
required for functional FGF signaling.
E-Syt2 Selectively Interacts with the Activated FGF
Receptor
Full-length Xenopus E-Syt2 localized to the plasma membranes
of embryonic blastomeres (Figure 2A) and of HEK293T cells
(Figure 5A). This and its requirement upstream of Ras suggested
that it might directly interact with the FGF receptor. When E-Syt2
was coexpressedwith a range of plasmamembrane receptors, it
showed a preference for Xenopus FGFR1 (Figure 2B). It further
displayed a similar level of interaction with the human FGFR1
and indeedwith all four receptor homologs FGFR1–4 (Figure 2C).
A weak, but reproducible, interaction was also noted with EGFR,
but no significant interaction with EphA4 (Winning et al., 1996) or
with the Activin/BMP receptor (Chang et al., 1997; Figure 2B).
Interaction of E-Syt2 with FGFR1 was found to be dependent
on a basal level of receptor activation, since treatment of cells
with the FGFR inhibitor SU5402 (EMD/Merck) abrogated the
interaction as well as receptor autophosphorylation (Figure 2D).
Further, addition of bFGF markedly enhanced the basal level
of interaction (Figure 2E). Enhancement of the interaction by
bFGF was noted whether FGFR1 was coimmunopreciptated
with E-Syt2 or E-Syt2 was coimmunoprecipitated with FGFR1
(upper and lower panels in Figure 2E). The weak interaction of
E-Syt2 with the EGFR receptor was also enhanced by receptor
activation and suppressed by the EGFR inhibitor tyrphostin
(AG1478, Sigma), but activation of the EphA4 receptor (Epp)
did not enhance its interaction with E-Syt2, despite strong auto-
phosphorylation (Figure S2). Expression of dominant-negative428 Developmental Cell 19, 426–439, September 14, 2010 ª2010 ElsEGFR in Xenopus in fact induces a mild XFD-like phenotype
(Amaya et al., 1993; Nie andChang, 2006). Hence, the interaction
of E-Syt2 with activated FGFR and possibly to a lesser degree
with activated EGFR provided a potential explanation for its
requirement in vivo.
Interaction of E-Syt2 with FGFR1 Is Independent
of Receptor Autophosphorylation Required
for Signal Transduction
Since E-Syt2 depletion prevented activation of the ERK pathway
by CA-FGFR1 but not by VRas, it must act downstream of
receptor activation and upstream of Ras (Figure 1D). To more
precisely determine the requirement for E-Syt2, we asked
whether or not it interacted with the activated receptor indepen-
dently of signal transduction. FGFR1 activation results in the
autophosphorylation of a number of tyrosines within its cyto-
plasmic domain. Phosphorylation of aa Y463 and Y766 are
required for recruitment of Crk, PLCg, and Shb, and for activa-
tion of the ERK pathway (Cross et al., 2002; Lundin et al.,
2003; Mohammadi et al., 1992; Ong et al., 2000). However,
neither a Y463F nor a Y766F mutation of FGFR1 affected the
ability of E-Syt2 to specifically recognize and interact with the
activated receptor (Figure 2F). Thus, the interaction of E-Syt2
with activated FGFR1 not only preceded Ras activation but
also the recruitment of key downstream effectors.
E-Syt2 Is Required for Endocytosis of Activated FGFR1
and for ERK Activation
The classical Synaptotagmins are believed to direct cargo pro-
teins to the Adaptin-2/clathrin endocytic pathway (Haucke and
De Camilli, 1999). Since it is generally accepted that receptor
endocytosis is important in growth factor signaling, we hypothe-
sized that E-Syt2 might be required for the endocytic trafficking
of FGFR. We, therefore, determined the kinetics of FGFR1 endo-
cytosis in E-Syt2-depleted ACs following bFGF stimulation
(Figure 3A; see Experimental Procedures). As expected, receptor
endocytosis was arrested at 4C even after FGF treatment. On
the other hand, at 22C a large proportion of cell surface receptor
was transported into endocytic vesicleswithin 5min of FGF treat-
ment, and by 15 min receptor internalization was essentially
complete. (Internalized FGFR colocalized with markers of early
endosomes when assayed in cell culture; see below.) E-Syt2
depletion very strikingly abrogated the rapid phase of receptor
endocytosis that occurred within the first 5 min of FGF treatment
(Figure 3A). This rapid phase of endocytosis was also efficiently
rescued by reintroduction of E-Syt2 (Figure S3). In contrast, after
15 min of FGF treatment, receptor endocytosis in the E-Syt2-
depleted ACs approached control levels. A higher level of
FGFR, however, remains associated with the plasma membrane
than in control ACs (Figure 3A).
ERK activation in control ACs closely correlated with the rapid
phase of receptor endocytosis, already being maximal after
5 min of FGF treatment and remaining high for at least 15 min,
before returning to the basal level by 30 min (Figure 3B).
E-Syt2 depletion abrogated the rapid phase of ERK activation
and though some ERK activity was detected at 15 min, it was
significantly lower than in control ACs. Thus, E-Syt2 was
required for the rapid phase of receptor endocytosis and for
the maximal and prolonged activation of ERK.evier Inc.
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Figure 2. E-Syt2 Is a Membrane Protein that Specifically Interacts with the Activated FGF Receptor
(A) E-Syt2-GFP and E-Syt2-Myc fusions were expressed in Xenopus embryos and visualized at blastula either by direct (-GFP) or indirect (-Myc) confocal
epifluorescence microscopy.
(B) E-Syt2 interacts selectively with FGFR1. HA-tagged E-Syt2 (HA-E-Syt2) was coexpressed with FLAG-tagged Xenopus FGFR1 (xFLAG-FGFR1), Xenopus
BMPR (FLAG-BMPR), human EGFR (FLAG-EGFR), or Xenopus Epp (EphA4) (Epp-FLAG) (Winning et al., 1996) in HEK293T cells and anti-FLAG-coimmunopre-
cipitated (I.P.) complexes were immunoblotted (I.B.).
(C) HA-tagged E-Syt2 (HA-E-Syt2) was also coexpressed with the FLAG-tagged human FGF receptors 1 to 4 (FLAG-hFGFR1, 2, etc) and analyzed for coimmu-
noprecipitation as in (B).
(D) E-Syt2 interacts selectively with the activated, tyrosine phosphorylated form of FGFR1. HA-E-Syt2 and FLAG-xFGFR1 were coexpressed in HEK293T cells,
FGFR1 inactivated or not with the specific inhibitor SU5402 and proteins immunoprecipitated and blotted as in (B).
(E) bFGF enhances the E-Syt2 interaction with FGFR1. FLAG-xFGFR1 and increasing levels of HA-E-Syt2 were coexpressed as in (B) and where indicated cells
were treated with bFGF. Extracts were then immunoprecipitated with either anti-HA or anti-FLAG antibodies and blotted as indicated. ‘‘+++’’ indicates highest
level of E-Syt2 transfection.
(F) The E-Syt2/FGFR1 interaction is independent of the recruitment of downstream factors to the receptor. FLAG-hFGFR1 and the point mutants Y463F and
Y766F were coexpressed with HA-E-Syt2, cells treated either with SU5402 or with bFGF as in (D) and (E), and anti-FLAG-coimmunoprecipitated (I.P.) complexes
immunoblotted (I.B.).
See also Figure S2.
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E-Syt2, an Endocytic Adaptor for FGFRAs expected, a dominant-negative (K44E) Dynamin mutant
also abrogated FGF-induced receptor endocytosis in ACs
(Figure 3C). Coexpression of Dynamin K44E inhibited CA-FGFR1
induction of Xbra to a similar degree as E-Syt2 depletion and,
as with depletion of E-Syt2, VRas rescued Xbra expression inDevelopmenK44E-Dynamin expressing ACs (Figures 3D and 1D). Chlor-
promazine, a specific inhibitor of the clathrin-mediated endo-
cytic pathway (Wang et al., 1993), suppressed Xbra induction
to a similar degree as E-Syt2 depletion and Dynamin-K44E
expression while nystatin, a specific inhibitor of the caveolartal Cell 19, 426–439, September 14, 2010 ª2010 Elsevier Inc. 429
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Figure 3. E-Syt2 Is Required In Vivo for FGF Receptor Endocytosis and Signaling via the Clathrin Pathway
(A) E-Syt2 depletion inhibits FGF receptor endocytosis in vivo. Each blastomere of four cell embryoswas injectedwith 6 pmol ofMorpholino C (Mo-C) and 20 pg of
XenopusMyc-FGFR1mRNA. ACs were then isolated and incubated with anti-Myc antibody to label surface receptors. After incubation with bFGF at 4C or 22C
for the indicated times, ACs were subjected to indirect immunofluorescence labeling to reveal receptor endocytosis. The upper panels show typical images and
the lower panel the statistical analysis of receptor internalization.
(B) Embryos were injected and ACs were isolated and treated with bFGF at 22C as in (A), before analysis of cell extracts for ERK and phospho-ERK levels by
immunoblotting.
(C) Dominant-negative Dynamin also inhibits FGFR1 endocytosis in vivo. ACs expressing Myc-FGFR1 alone or with Dynamin K44E (Dyn-K44E) were prepared
and treated with bFGF and were analyzed for receptor endocytosis as in (A). In (A) and (C), ‘‘n’’ indicates the number of cells scored, scale bar in micrographs
represents 30 mm, and error bars indicate the standard error.
(D) Induction of Xbra in ACs requires FGFR1 endocytosis upstream of VRas. Embryos were injected with either CA-FGFR1 or VRas and DynK44E mRNAs and
Xbra and ODC mRNA levels determined by RT-PCR.
(E) ACs expressing CA-FGFR1 were also treated with clathrin or caveolin inhibitors, chlorpromazine and nystatin before RT-PCR analysis as in (D).
In (D) and (E), +RT and –RT refer to control PCR analysis of whole embryo RNAs with and without reverse transcriptase.
See also Figure S3.
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Figure 4. E-Syt2 Interacts with Adaptin-2
to Modulate Receptor Endocytosis, ERK
Activation, and Xbra Induction
(A) E-Syt2 interacts with the endogenous AP-2
tetramer. HA-E-Syt2 and Myc-tagged FGFR1
(Myc-FGFR1) were coexpressed in HEK293T
cells stimulated or not with bFGF. Endogenous
AP-2 complexes were immunoprecipitated with a
b2-Adaptin-specific antibody or a nonspecific
control antibody (IgG Ctrl) and I.B.
(B) Both E-Syt2 and FGFR1 interact with the AP-2
complex. b2-adaptin (FLAG-b2-Ad) was coex-
pressed with FGFR1 (Myc-FGFR1) and with
increasing amounts of E-Syt2 (HA-E-Syt2) and
complexes were immunoprecipitated with an
anti-FLAG antibody (I.P. FLAG). The upper panels
show immunoblots for the coprecipitated proteins
and the lower panels show protein levels in the
input protein lysate.
(C) E-Syt2 gain of function also inhibits bFGF and
activated FGFR1 (CA-FGFR1)-mediated, but not
Activin-mediated Xbra induction in ACs.
(D) Left panel, constitutively activated-ERK (CA-
ERK) but not constitutively activated PI3K (PI3K-
CAAX) expression rescues E-Syt2 inhibition of
Xbra induction by CA-FGFR1 in ACs. Right panel,
consistent with this PI3K-CAAX activation of Akt
in ACs is not strongly affected by E-Syt2 gain of
function.
(E) E-Syt2 gain of function inhibits ERK activation
by CA-FGFR1 (anti-phospho-Erk immunoblot) in
ACs.
See also Figure S4.
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E-Syt2, an Endocytic Adaptor for FGFRpathway (Rothberg et al., 1992), had little effect (cf. Figure 3E
with Figures 1D and 3D). Thus, in the Xenopus system, functional
signaling through FGFR1 occurred predominantly via the cla-
thrin-mediated pathway. Together, the data supported the
contention that E-Syt2 depletion inhibited FGF signaling by sup-
pressing the rapid phase of clathrin-dependent receptor endo-
cytosis. E-Syt2 appeared, then, to act as an essential endocytic
adaptor in FGF signaling. Since it directly recognized the acti-
vated FGF receptor independently of downstream signaling
events, the data also suggested that E-Syt2 acted at a very early
stage of endocytic trafficking.
E-Syt2 Interacts with the Adaptin-2 Complex
Synaptotagmin 1 (Syt1) catalyzes endocytosis via the clathrin-
mediated pathway by targeting cargo proteins to Adaptin-2
(AP-2) via an interaction that involves its C2B domain (HauckeDevelopmental Cell 19, 426–439, Seand De Camilli, 1999; Haucke et al.,
2000; Poskanzer et al., 2006; von Poser
et al., 2000; Zhang et al., 1994). We,
therefore, tested whether E-Syt2 inter-
acted with AP-2. In vitro ‘‘pull-down’’
assays showed that the bacterially
expressed C2A, -B, and -C domains of
E-Syt2 all bound the in vitro translated
a subunit of AP-2, while only C2B and -C
also bound the m and s subunits and none
of the C2 domains bound the b subunit(Figure S4A). This was analogous to interactions of Syt-1 with
the a and m subunits of AP-2 (Haucke et al., 2000).
Consistent with the in vitro interactions, immunoprecipitation
of the endogenous AP-2 complex from HEK293T cells with
an b2-Adaptin-specific antibody was found to coprecipitate
E-Syt2 (Figure 4A). Since the b2 subunit did not directly interact
with E-Syt2, this demonstrated that E-Syt2 indeed interacted
with the intact AP-2 complex. The interactionwas alsodetectably
enhanced by bFGF stimulation, suggesting that endogenous
FGFR might cooperate in the formation of the AP-2/E-Syt2
complex. To investigate this further, FLAG-tagged b2-Adaptin
was coexpressed with E-Syt2 and with FGFR1 in HEK293T
cells. Both E-Syt2 and FGFR1were observed to coimmunopreci-
pitate with FLAG-b2-Adaptin, whether expressed separately or
together, suggesting the possibility of a tripartite complex (Fig-
ure 4B; Figures S4B and S7A). However, stepwise increase inptember 14, 2010 ª2010 Elsevier Inc. 431
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betweenFGFR1andAP-2 (b2-Adaptin) (Figure4B), and this effect
was fully reproducible (Figure S4B). These data suggested that
either the interactions of E-Syt2 with AP-2 and with FGFR1
were exclusive or that nonstochiometric levels of E-Syt2 inde-
pendently titrated AP-2 and FGFR1 and in so doing inhibited
the formation of the tripartite complex. Such competition is
a common but poorly documented occurrence when adaptor
proteins are overexpressed (Ruan et al., 1999). Since E-Syt2
was found to interact with FGFR1 and with AP-2 via distinct
and distal domains (Figures 6D, 6E, and 7D; Figures S4A and
S6A), it seemed unlikely, but not impossible, that AP-2 and
FGFR1 simply competed for binding to E-Syt2. Thus, E-Syt2
either interacted with both FGFR1 and AP-2 to form a tripartite
complex, or these interactions were exclusive and occurred
independently.
E-Syt2 Gain of Function Inhibits Functional FGF
Signaling
Since overexpression of E-Syt2 interfered with the interaction
between FGFR1 and AP-2, we argued that it should also inhibit
functional FGF signaling. Consistent with this, gain of E-Syt2
function in vivo-induced trunk shortening similar to that observed
with E-Syt2 depletion (Figure S4C), and suppressed the induc-
tion of Xbra in embryo ACs by bFGF and by CA-FGFR1, but
not by Activin (Figure 4C). Further, this inhibition could be
rescued by activated ERK (CA-ERK), but not by activated PI3K
(PI3K-CAAX) despite the latter’s ability to activate Akt in ACs
(Figure 4D). (Though earlier studies suggested the FGF or Activin
pathways were interdependent, more recent work has shown
that this is not the case [Tsang et al., 2002; Zhao et al., 2008].)
E-Syt2 gain of function also inhibited the activation of ERK by
both bFGF and by CA-FGFR1 (Figure 4E). Thus, E-Syt2 gain of
function specifically suppressed the induction of Xbra and the
activation of ERK by the FGF pathway.
E-Syt2 Gain of Function Inhibits Endocytosis
of Activated FGFR1
The data suggested that the dominant-negative gain-of-function
effects of E-Syt2 could be due to inhibition of FGFR1 endocy-
tosis. Since E-Syt2 had been observed to compete the FGFR1/
AP-2 interaction in HEK293T cells (Figure 4B; Figure S4B), we
studied the effects of E-Syt2 gain of function on internalization
of FGFR1 in these cells. In FGF-treated control cells, internaliza-
tion of FGFR1 was rapid and complete, only 7% displaying
no internalization 20 min after FGF addition (Figures 5A and B).
In contrast, 45% of E-Syt2 expressing cells still showed no
receptor endocytosis at all 20 min after FGF addition. FGFR1
positive vesicles were found to colocalize with the early endo-
some marker EEA1 already 5 min after FGF addition and
15min later limited colocalization with the late endosomemarker
Rab7 was also observed (Figure S5A). Inhibition of endocytosis
was specific to the FGF receptor, since the parallel uptake
of transferrin was unaffected (Figure S5B). Further, FGFR1 endo-
cytosis in the HEK293T cells was clathrin dependent as deter-
mined by its sensitivity to chlorpromazine but not to nystatin
(Figure S5C). When receptor internalization was blocked by
E-Syt2 gain of function, both FGFR1 and E-Syt2 remained fully
accessible on the plasma membrane to biotin modification,432 Developmental Cell 19, 426–439, September 14, 2010 ª2010 Elsclearly showing that the receptor did not enter the endocytic
pathway (Figure 5C). Thus, E-Syt2 gain of function blocked
receptor endocytosis at a step preceding pinching-off of the
clathrin-coated pit.
Consistent with the block to receptor internalization, E-Syt2
gain of function in HEK293T cells also significantly suppressed
activation of ERK by FGF (Figure 5D). Thus, as for E-Syt2 gain
of function and depletion in ACs, the level of ERK activation
correlated closely with the degree of internalization of activated
FGFR1 in the HEK293T cell system.
Dominant-Negative Effects of E-Syt2 Require Both
Putative-TM and C2C Domains
Since E-Syt2 gain of function behaved as a dominant-negative
mutation, it was used to map the functional domains of E-Syt2
in FGF signaling. Deletion of either the putative-TM or the C2C
domain of E-Syt2 was sufficient to abrogate its ability to inhibit
Xbra induction by CA-FGFR1 in Xenopus ACs (Figures 6A
and 6B). The same mutants were assayed for their dominant-
negative effects on endocytosis in HEK293T cells, and here
again both the TM and C2C domains were found to be essential,
only full-length E-Syt2 displaying an ability to block endocytosis
of activated FGFR1 (Figure 6C). Though the C-terminal deletion
mutants DC2C, DC2BC, and DC2ABC were partly cytosolic, all
mutants displayed a significant degree of association with the
plasmamembrane. Surprisingly, theDTMmutant, lacking a puta-
tive transmembrane domain, was almost exclusively associated
with the plasma membrane. Thus, the loss of dominant-negative
function in E-Syt2 mutants was not simply due to a failure to
decorate the plasma membrane and colocalize with FGFR1.
The Putative-TM Domain of E-Syt2 Is Sufficient
for Selective Interaction with Activated FGFR1
We argued that one or more of the mutations may have affected
the ability of E-Syt2 to interact with the FGF receptor. Each
E-Syt2 mutant was therefore assayed for interaction with
FGFR1 by coimmunoprecipitation (Figure 6D; Figure S6A). We
found that deletion of the N-terminal domain including the puta-
tive-TM domain (DTM) eliminated the interaction with FGFR1
and that this same domain (aa 1–312, DC2ABC) was sufficient
for interaction with FGFR1. More importantly, this N-terminal
domain encoded the receptor specificity of E-Syt2, its receptor
binding being in greater part dependent on receptor activation
(Figure 6E). (As will be seen, this was also the case for human
E-Syt2 [Figure 7D]). Expression of differentially tagged E-Syt2
mutants revealed that like the Synaptotagmins, E-Syt2 dimer-
ized or oligomerized, and that this required the same N-terminal
domain found to interact with FGFR1 (Figures S6B and S6C).
Thus, the N-terminal domain of E-Syt2 was responsible for inter-
action with FGFR1 and for E-Syt2 oligomerization but was not
sufficient for the E-Syt2 dominant gain-of-function effects, which
also required the C2C domain.
The C2C Domain Constitutes a Phospholipid Binding
Domain
C2 domains often display selective phospholipid binding and
phospholipids are known to be important in the internalization
of receptor complexes (Geppert et al., 1994). In fact, the C2C
domain of human E-Syt2a was shown to be sufficient forevier Inc.
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See also Figure S5.
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E-Syt2, an Endocytic Adaptor for FGFRlocalization to the plasma membrane of HEK293T cells (Min
et al., 2007). In agreement with these data, we noted a significant
increase in the cytosolic localization of Xenopus E-Syt2 when the
C2C domain was deleted (Figure 6C) and found that fusion of
the C2C domain to a nuclear-targeted GFP was sufficient to
displace it to the plasma membrane (Figure S6D). A previous
study showed that while the combined C2AB domains of human
E-Syt2a displayed Ca2+-dependent binding to synthetic phos-
phatidyl-serine/-choline liposomes, C2C did not bind these lipo-
somes (Min et al., 2007). To further investigate the activities of
the C2C domain, we assayed its ability to bind a broad range
of immobilized phospholipid species in comparison with the iso-
lated C2A and C2B domains. In this assay, C2C displayed strong
phospholipid binding with a preference for phosphoinositide
phosphate (PI-P) species (Figure S6E) and, consistent with the
lack of a consensus motif for Ca2+ coordination (Cheng et al.,
2004; Min et al., 2007), binding was not dependent on the
presence of Ca2+. Thus, the ability of the C2C domain to bindDevelopmenphosphoinositol species and to target E-Syt2 to the plasma
membrane may in part explain the functional requirements for
this domain.
E-Syt2 Function Is Conserved in Human
The closest human ortholog of Xenopus E-Syt2 is translated
from a major mRNA splice variant that encodes hE-Syt2b
differing in its N-terminal domain from the previously identified
hE-Syt2a (Min et al., 2007; Figure S1A).When expressed in
HEK293T cells, human E-Syt2b was found to interact with both
human and Xenopus FGFR1 (Figure 7A). Further, immunoprecip-
itation of endogenous hE-Syt2 from bFGF stimulated HEK293T
cells, using specific anti-E-Syt2 antibodies, coimmunoprecipi-
tated the endogenous FGFR1 receptor, indicating that this
interaction occurred naturally within these cells (Figure 7B). In
common with its Xenopus ortholog, hE-Syt2b displayed a strong
and specific interactionwith the activated form of human FGFR1,
and this interaction required only the N-terminal domain oftal Cell 19, 426–439, September 14, 2010 ª2010 Elsevier Inc. 433
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See also Figure S6.
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E-Syt2, an Endocytic Adaptor for FGFRhE-Syt2b (Figures 7C and 7D). Human E-Syt2b also interacted
with AP-2 (again FLAG-tagged on the b subunit) and both it
and FGFR1 could be coprecipitated together with AP-2
(Figure S7A). hE-Syt2b localized to the plasma membrane, and
hE-Syt2b gain of function blocked FGF-dependent internaliza-
tion of hFGFR1 (Figure S7B). Thus, human E-Syt2b displayed
very similar, if not identical, functionality to its Xenopus ortholog,434 Developmental Cell 19, 426–439, September 14, 2010 ª2010 Elsstrongly suggesting that E-Syt2 function in the FGF signaling
pathway is conserved from amphibia to mammals.
DISCUSSION
Of 16 vertebrate synaptotagmins, functions have as yet been
assigned to very few. These functions are mostly related toevier Inc.
AhE-Syt2b
xFGFR1
hFGFR1
hE-Syt2bI.B. HA
I.B. FLAG
I.B. HA
Lysate
HA-hE-Syt2b
FLAG-hFGFR1
FLAG-xFGFR1
I.P
.
 
FL
AG
C
I.B. HA
I.B. FLAG
FLAG-hFGFR1
HA-hE-Syt2b
+-
+ +
- -
+
+
+SU5402 25µM
I.P
.
 
 
 
FL
AG
Lysate:
I.B. HA
I.B. FLAG
I.B. p-Tyr
E-Syt2b
E-Syt2b
FGFR1
FGFR1
pY-FGFR1
D
hE
-S
yt
2
Pr
eI
m
.
I.B.
FGFR1
I.B.
hE-Syt2
I.P.:-
B
+ FGF
+ FGF
E-Syt2 recruitment to
activated FGFR1
Recruitment to 
existing pit
Assembly of 
pit around activated
receptors
Or
hFGFR1-HA +++ + +
FLAG-hE-Syt2b WT +-+ - -
FLAG-hE-Syt2b ΔC2ABC - -+ + -
FGFR1
FGFR1
hE-Syt2b
hΔC2ABC
Lysates
I.B. HA
I.B. FLAG
I.B. HA
I.P
.
 
FL
AG
E
++ --SU5402 -
-- ++bFGF -
893
312
TM C2A C2B C2C
1
1
E-Syt2
AP-2
Clathrin
FGFR1
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(A) Human E-Syt2b (HA-hE-Syt2b) was coexpressed with Xenopus or human FGFR1 (FLAG-xFGFR1 or -hFGFR1) in HEK293T cells, the receptors immunopre-
cipitated and proteins analyzed by immunoblotting.
(B) Endogenous human E-Syt2 was immunoprecipitated from a whole-cell extract using xE-Syt2 antibody #2 and the precipitate immunoblotted for both hE-Syt2
(hE-Syt2#Pr0863-2932r, see Experimental Procedures) and hFGFR1 (Flg #121, Santa Cruz Biotechnology).
(C) Human E-Syt2b interacts specifically with activated FGFR1. hE-Syt2b (HA-hE-Syt2b) was coexpressed with human FGFR1 (FLAG-hFGFR1) in HEK293T cells
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(E) Potential E-Syt2 functions in FGF signaling. Two possible modes of action are suggested; see text for more detail.
See also Figure S7.
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E-Syt2, an Endocytic Adaptor for FGFRneurotransmission, despite broad expression profiles in non-
neuronal tissues, e.g., (Andrews and Chakrabarti, 2005). Three
synaptotagmin-related protein families, the Ferlins, MCTPs,
and the E-Syts, are broadly expressed and each is characterized
by a transmembrane domain andmultiple C2 domains. Of these,
only the E-Syts are like the synaptotagmins in having anDevelopmenN-terminal transmembrane domain and most closely resemble
the Tricalbins, which are implicated in receptor endocytosis in
yeast (Creutz et al., 2004). We found that E-Syt2 was essential
for FGF signaling during early Xenopus development. Antisense
depletion of E-Syt2 inhibited induction of the early mesodermal
marker Xbra by FGF and this inhibition could be rescued bytal Cell 19, 426–439, September 14, 2010 ª2010 Elsevier Inc. 435
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E-Syt2, an Endocytic Adaptor for FGFRVRas, suggesting that E-Syt2 was required upstream of Ras.
Depletion of E-Syt2 prevented a rapid phase of FGF receptor
endocytosis and the temporally linked activation of ERK.
E-Syt2 specifically recognized activated FGFR1 on the plasma
membrane and also interacted with the Adaptin-2 (AP-2)
complex. Though recognition depended on receptor catalytic
activity, it was independent of key receptor autophosphorylation
events and hence of signal transduction, suggesting the interac-
tion with E-Syt2 was one of the earliest events following receptor
activation. E-Syt2, to our knowledge, presents the first example
of an endocytic adaptor able to selectively recognize the acti-
vated FGF receptor prior to signal transduction and to function-
ally link it with the AP-2/clathrin pathway.
The data suggest that E-Syt2 either links the activated
receptor to AP-2 and clathrin or catalyzes this interaction by pre-
senting and handing-off the receptor to AP-2, a mechanism
similar to that suggested to explain Syt-1’s ability to catalyze
interactions between AP-2 and cargo proteins (Haucke and
De Camilli, 1999). E-Syt2 might then stimulate the interaction
of the activated receptor with nascent clathrin-coated pits or
catalyze the de novo formation of pits around activated recep-
tors (Figure 7E). Given that Syt-1 has been found to both stimu-
late and regulate the de novo formation of clathrin-coated pits
(von Poser et al., 2000), it is tempting to suggest that the latter
may in fact be the case.
To our knowledge, E-Syt2 is also the first endocytic adaptor to
be identified for the FGF pathway. Several other membrane
proteins have been implicated in mesoderm induction by FGF.
Sef (Furthauer et al., 2002; Tsang et al., 2002) and xFLRT3
(Bottcher et al., 2004) are both transmembrane proteins shown
to interact directly with the FGF receptor and to modulate FGF
signaling, see (Bottcher and Niehrs, 2005). Further, in cell culture
N-CAM (Cavallaro et al., 2001) and N-cadherin (Suyama et al.,
2002) have been shown to modulate FGF signaling. However,
unlike E-Syt2 none of these proteins show homologies with
potential components of the endocytic machinery nor do they
display obvious endocytic activity. Further, their actions have
been suggested to be tissue specific. The broad tissue and
temporal expression profile of E-Syt2 in Xenopus along with its
requirement for signaling in vivo suggest it is an essential compo-
nent of the FGF signaling pathway.
The requirement for receptor endocytosis in FGF signaling
has been the subject of some controversy. Some studies
argue that membrane localization of activated FGFR1 results
in higher MAPK activation (Dammai et al., 2003; Suyama
et al., 2002), while others have found that endocytosis or traf-
ficking are required for full FGFR1 signaling (Bryant et al.,
2005; Reilly and Maher, 2001; Vecchione et al., 2007). Further,
FGF receptor endocytosis is believed to occur via both clathrin
and caveolin-dependent pathways (Belleudi et al., 2007; Bryant
et al., 2005; Wiedlocha and Sorensen, 2004). Here, we
show that inhibition of FGFR1 endocytosis, by loss or gain of
E-Syt2 function, by dominant-negative dynamin expression or
chlorpromazine inhibition, suppresses mesoderm induction,
Xbra expression, and ERK activation. Thus, our data demon-
strate the necessity of endocytosis via the clathrin pathway
for functional FGF signaling in vivo, and as such parallel the
findings for the EGF receptor (Vieira et al., 1996). Further, we
demonstrate that rapid FGFR endocytosis is essential for func-436 Developmental Cell 19, 426–439, September 14, 2010 ª2010 Elstional signaling and ERK activation during Xenopus embryo-
genesis.
Since the synaptotagmins function both in endo- and exocy-
tosis (Sudhof, 2004), it is tempting to speculate that E-Syt2 could
also be implicated in the exocytosis and/or the recycling of the
FGFR1, a possibility we are currently pursuing. In this context,
it is worth noting that other unrelated C2 domain proteins have
been identified as important in cell trafficking events (Gallagher
and Knoblich, 2006; Jaekel and Klein, 2006) and for cell adhesion
(Pilot et al., 2006).
EXPERIMENTAL PROCEDURES
Plasmid Constructs
Full-length E-Syt2 cDNA was amplified from an I.M.A.G.E. clone 5543078
(GenBank NM_001087117). All the mutants or epitope-tagged constructs
were created by PCR from the original I.M.A.G.E. clone and subcloned in
pT7Ts-HA (P. Krieg, modified) and pCDNA3. A short cDNA encoding human
E-Syt2b was obtained from Kazusa DNA Research Institute (KIAA1228) and
the missing 50 sequences obtained by PCR amplification from HEK293T cells.
Sequencing showed the product to be identical to GenBank NM_020728.
It was then subcloned into pT7Ts-HA and pCDNA3. Xenopus FGFR1 and
CA-FGFR1 (K562E) were from R. E. Friesel and C. Niehrs, and FLAG-b2-adap-
tin from S. Laporte. Wherever the source of E-Syt2 and FGFR1 is not specified
the Xenopus forms were used. The position of epitope tags is indicated as
N- or C-terminal by prefixing or suffixing the epitope indicator.
Morpholinos and Antibodies
Five Morpholino sequences against the Xenopus E-Syt2 cDNAs were made,
two complementary to the sequence downstream from the ATG start codon
referred to as A and A-like and two complementary to the adjacent 50 UTR
sequence referred to as B and B-like, and one complementary to a 50 UTR
sequence further 50 referred to as C: A; TCTCTGCGCTGCTCTCGGAAGACAT,
A-like; 50-TCTCAGCGCCGCTCTCGGAAGCCAT, B; 50-GTGAATTAACTGCG
ACAGAGAGAGA, B-like; 50-GTGAATTGACTGCGCCTGAGAGAGA, C; 50-CT
CTTCCAGCCCTGCCTCAGCCCAA. A 5 mismatch Morpholino was used as
control; 50-GTCAATTAAGTGCCACACAGACAGA. Of these five Morpholinos
only the B and C Morpholinos downregulated E-Syt2 protein levels and had
significant biological effects. The rabbit polyclonal antibody xE-Syt2#2 was
generated from a bacterially expressed protein containing aa 97–180 of
Xenopus E-Syt2. The rabbit polyclonal antibody hE-Syt2#Pr0863-2932r was
generated and affinity-purified against aa 802–822 of hE-Syt2b (NM_020728)
(21st Century Biochemicals).
Whole-Mount In Situ Hybridization
Whole-mount in situ hybridization was performed on albino or pigmented
Xenopus laevis (Nasco) as described (Harland, 1991). The probe used for
E-Syt2 was to nucleotides 2506–2765 (NM_001087117).
Embryo Manipulation, Injection, and Explants
Embryos were staged using the Nieuwkoop and Faber tables (Nieuwkoop and
Faber, 1967). Xenopus embryos in 2% Ficoll (GE HealthCare) in 0.53 MMR
were injected with either mRNA or antisense Morpholino oligonucleotides at
the two or four cell stage (AC explants). mRNA was produced using the
mMessage kit (Ambion). The amount of Morpholino or mRNA injected was
as indicated. Animal Cap (AC) explants were removed at stage 8–9 using
forceps on agarose coated dishes in 1 3 Barth’s medium and cultured in
0.5 3 Barth’s medium in parallel with control. Ventral marginal zone (VMZ)
explants were isolated at stage 10.5 using an eyebrow knife on agarose coated
dishes in 13 Barth’s medium. bFGF was purchased from Sigma and Activin A
from R&D.
Gene Expression Analysis by RT-PCR
Total RNA was prepared using Trizol (Invitrogen). RT-PCR was performed
using the primers, RT-PCR protocol, and PCR cycles standardize by theevier Inc.
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Xenbase (http://www.xenbase.org).
Pull-Down and Phospholipid Binding Assays
Pull-downs were carried out essentially as in Vadlamudi et al. (2002). Phospho-
lipid binding assays were performed on PIP Strips (Echelon) essentially as in
Schulz and Creutz (2004).
Cell Culture, Transfection, and Inhibitors
HEK293T cells were cultured in Dulbecco’s modified Eagle’s medium supple-
mented with 10% fetal bovine serum (Wisent). 1.25 3 106 293T cells were
seeded on poly-L-lysine (1 mg/ml) (Sigma) treated 60 mm Petri dishes 24 hr
prior to transfection. Transfections were performed by calcium phosphate
precipitation as described (Gingras et al., 2002), for 7 hr in the presence of
25 mM chloroquine (Sigma) using 8 mg of DNA. For cotransfections the ratio
of DNA was 1:1 unless otherwise stated. Where indicated, cells were treated
for 20 min with 20 ng/ml of bFGF (Invitrogen) or EGF (Invitrogen), for 16 hr
with 25 mM SU5402 (EMD/Merck) or 70 min with 30 nM tyrphostin (AG 1478,
Sigma), or for 1 hr either with chlorpromazine (Sigma), 10 mg/ml, or with
nystatin (Sigma), 10 mg/ml. For AC experiments, the inhibitors were added
immediately after AC isolation.
Coimmunoprecipitation
HEK293T cells were processed for coimmunoprecipitation 24 hr posttransfec-
tion. Cells were washed twice with ice-cold PBS and lysed in 300 ml (per 60mm
dishes) of coimmunoprecipitation buffer, essentially as (Bokoch et al., 1996).
For Western blotting, antibodies were used at 1/5000 (HA), 1/1000 (Myc,
Cell Signaling; E-Syt2), 1/400 (FLAG, Sigma), 1/5000 (Phospho-Erk, Sigma;
b2-Adaptin, BD Biosciences) and 1/3000 (GST, Sigma) and 1/10,000 (anti-
phosphotyrosine PY99, Santa Cruz Biotechnology).
Imaging of Proteins in Xenopus
Embryos expressing fluorescent proteins were dissected as necessary and
fixed (3.7% formaldehyde, 1 mM MgCl2 in PBS) for 20 min at room tempera-
ture. Explants were washed four times in PBS before mounting in 1:1 glycine
buffer: glycerol (glycine buffer; 0.2 M glycine, 0.3 M NaCl, 0.175 M NaOH,
15mMNaN3). For immunofluorescence in ACs, embryoswere fixed inMEMFA
for 1 hr, dehydrated in methanol, and permeabilized for 2 hr in Dent’s fixative.
ACs were rehydrated in PBS and blocked with 10% goat serum and 2% BSA
(Sigma) for 2 hr at room temperature. Both primary and secondary antibody
incubations were performed overnight at 4C on a Nutator. Five washes of
1 hr each were performed at room temperature after each antibody incubation.
Images were obtained on an UltraView spinning disk microscope (Perkin-
Elmer).
Biotin Labeling, Receptor Uptake Assays, and Immunofluorescence
For receptor uptake assays in ACs, four cell stage embryos were injected with
mRNA encoding Myc-xFGFR1 with E-Syt2 or control Morpholino. ACs were
removed at stage 9 and incubated for 1 hr with Myc antibody in 0.33 Barth’s,
washed twice in 0.3 3 Barth’s, and incubated for different times in 0.3 3
Barth’s plus 20 ng/ml bFGF (Sigma) and 5 mg/ml of heparin (Sigma). They
were thenwashed twice in PBS plusMgCl2 (1mM) and fixed in 4%paraformal-
dehyde for 20 min at 37C. ACs were permeabilized in 0.2% Triton X-100
(Sigma), blocked with 10% goat serum (Wisent) in PBS-MgCl2 for 1 hr at
room temperature , and incubated with a-rabbit Alexa-488 (1/250, Invitrogen)
for 1 hr before mounting (1:1 glycine buffer: glycerol). 3D images stacks were
obtained on an UltraView spinning disk microscope (Perkin-Elmer) and
analyzed using Volocity (Perkin-Elmer). FGFR1 positive vesicles at least
2 mm from the plasma membrane were counted for each cell throughout
15 optical sections (7.5 mm).
Biotin labeling was performed as in Lee et al. (2006), and in-cell receptor
uptake assay as inWernick et al. (2005) with the difference that aMyc antibody
(Abcam, ab9106) was used at a concentration of 5 mg/ml. 293T cells were
exposed to 20 ng/ml of bFGF and 5 mg/ml of heparin (Sigma) at 37C for
different times. Receptor colocalization assays with endosomal markers
were performed essentially as for uptake assays. However, the second anti-
body labeling after cell fixation was performed in two steps. Mouse anti-
FLAG antibody bound plasma membrane (external) FGFR1 was visualizedDevelopmen(and saturated) before cell permeabilization by incubation with an Alexa405-
conjugated goat anti-mouse antibody. After, permeabilization with Triton X-
100, mouse anti-FLAG antibody bound to endocytosed (internalized) FGFR1
was detected with an Alexa488-conjugated goat anti-mouse antibody. EEA1
and Rab7 were labeled with first antibody (respectively C45B10 and D95F2,
Cell Signaling) immediately after cell permeabilization and revealed with
Alexa568 conjugated goat anti-rabbit antibody in parallel with detection of
endocytosed FGFR1. 3D colocalization of endocytosed FGFR1 with EEA1 or
Rab7 was determined on the three-color confocal image stacks using Volocity
software (Perkin-Elmer).
For transferrin uptake assays 293T cells were processed as for an antibody
uptake assay. Transferrin-Alexa-568 20 mg/ml (Invitrogen) was added with the
bFGF and heparin and cells were incubated at 37C for 20 min. Immunofluo-
rescences were carried out as described above with the difference that an
a-mouse Alexa-405 (Invitrogen) was used as secondary antibody and imaging
was performed on a FV1000 confocal microscope (Olympus).SUPPLEMENTAL INFORMATION
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